WILLOW ANNOUNCES COLLABORATION WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP A MORE COST-EFFECTIVE, SUSTAINABLE PROCESS FOR A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT
Sunnyvale, California – January 31, 2024 – Willow Biosciences Inc. (“Willow“) (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, today announced a collaboration with a leading Active Pharmaceutical Ingredient (“API”) manufacturer to develop a more sustainable, cost-effective manufacturing route for their largest product sold globally. Willow’s […]
WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
Sunnyvale, California – January 16, 2024 – Willow Biosciences Inc. (“Willow“) (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients, today announced a collaboration with Enterin, Inc. (“Enterin”), a clinical stage biopharmaceutical company pioneering novel treatments that target neurodegenerative and metabolic disorders, to develop new sustainable manufacturing […]
WILLOW PLANS FOR SIGNIFICANT GROWTH IN 2024 ON THE BACK OF A SUCCESSFUL 2023
Estimated FY 2023 revenues in excess of $1.3 million is a record year for the Company Anticipate closing at least three new partnership development agreements including one for our corticosteroid API program, and one new commercial agreement under an existing partnership development program FY 2024 revenues are expected to increase by more than 100%, which […]
WILLOW AND LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY ADVANCE DEVELOPMENT PROGRAM TO MANUFACTURE SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
Program brings immediate R&D revenue and first commercial supply revenue as early as 2024 Program further validates Willow’s BioOxiTM technology and focus on commercial execution and aligns with its strategic focus on near term revenue generation Sunnyvale, California – December 7, 2023 – Willow Biosciences Inc. (“Willow“) (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on […]
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Record revenues for the third quarter and the nine months ended September 30, 2023 Patent application filed for a process to produce corticosteroids at an expected significant cost reduction to current manufacturing cost Signed two new program agreements, and advanced three programs to the next phase of development toward commercialization Sunnyvale, California – November 14, […]
WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING
Calgary, Alberta – October 10, 2023 – Willow Biosciences Inc.(“Willow” or the “Company“) (TSX: WLLW; OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to announce the completion of its previously announced offering of convertible debenture units of the Company (the “Debenture Units“), on a non-brokered private […]